Overview
Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.
Work here?Claim your company
Simplify's Take
What believers are saying
- August 2026 NMPA accepted partner MediLink's Tam-Peli NDA, validating China execution.
- Caidya’s APAC-heavy model fits sponsors needing China speed and regulatory navigation.
- Rubicon’s $165 million 2025 growth capital still funds expansion and integration.
What critics are saying
- Combining Caidya and Simbec-Orion creates integration failure risk through 2026-2027.
- CRO rivals Fortrea, ICON, and Medpace outspend Caidya on scale and technology.
- Failed integration traps Caidya as a subscale CRO and forces retrenchment.
What makes Caidya unique
- June 30, 2026 deal with Simbec-Orion adds Phase I clinical pharmacology to Caidya.
- Barbara Lopez Kunz now runs a CRO spanning Europe, Americas, APAC, and China.
- Michael Clay’s February 2026 COO hire deepens global delivery across 60 countries.
Help us improve and share your feedback! Did you find this helpful?